Schnitzler Syndrome

1. Disease Information

Overview. Schnitzler syndrome is a rare, acquired, late-onset autoinflammatory disorder defined by the combination of a chronic urticarial rash plus a monoclonal gammopathy (IgM in >90% of cases, IgG in a minority), accompanied by signs of systemic inflammation: recurrent fever, bone pain, arthralgia/arthritis, lymphadenopathy, fatigue, and markedly elevated acute-phase reactants. It sits at the crossroads of autoinflammation and clonal B-cell/plasma-cell disease, and is driven by dysregulated interleukin-1β (IL-1β) signaling — the basis for its near-pathognomonic response to IL-1 blockade. First described by the French dermatologist Liliane Schnitzler in 1972.

"Schnitzler syndrome is a rare disorder characterized by a chronic urticarial rash and monoclonal gammopathy (IgM in more than 90% of the cases)… Interleukin-1 is considered the key mediator, and interleukin-1 inhibitors are considered first line treatment." (Case series, Case Reports in Rheumatology 2018)

Key identifiers (verify against MONDO/Orphanet at curation time): - Orphanet: ORPHA:37748 (Schnitzler syndrome) — CC-BY, citable as ORPHA:37748 - MONDO: MONDO:0008756 (Schnitzler syndrome) — suggested primary MONDO ID; confirm with runoak -i sqlite:obo:mondo info MONDO:0008756 -O obo - OMIM: No dedicated OMIM phenotype number — the disorder is acquired/sporadic, not Mendelian, so OMIM does not assign a gene-disease MIM. (This is itself a meaningful curation fact.) - ICD-10: No specific code; coded pragmatically under D47.2 (monoclonal gammopathy of undetermined significance) or L50.8 (other urticaria). ICD-11: best mapped under autoinflammatory/urticarial categories (e.g., EB00 urticaria family / 4A60 autoinflammatory) — no unique stem code. - MeSH: Schnitzler Syndrome (descriptor present in MeSH).

Synonyms / alternative names: Schnitzler's syndrome; chronic urticaria with macroglobulinemia; urticarial vasculitis–macroglobulinemia (historical, imprecise).

Data derivation: Disease-level aggregated resources — Orphanet, expert reviews, and pooled case-series — not EHR/individual-patient registries. The single most useful quantitative source is the pooled 281-case review (PMID:25905009).

2. Etiology

Causal factors. Schnitzler syndrome is acquired and sporadic; there is no inherited cause. The proximate driver is inappropriate activation of the innate immune system with IL-1β overproduction, occurring in the context of a clonal IgM (rarely IgG) gammopathy. The relationship between the monoclonal component and the inflammation is not settled — they may be parallel manifestations of one clonal/innate-immune lesion rather than one causing the other.

Genetic risk factors. - No germline pathogenic variant is required or established. Critically, despite the clinical overlap with cryopyrin-associated periodic syndromes (CAPS), NLRP3 germline mutations are absent: "no somatic or germline variations of NLRP3 were identified by deep NGS in two large cohorts of 21 and 40 patients" (PMID:38927050). - Somatic MYD88 L265P — a recurrent gain-of-function variant — has been detected in a subset of patients (in clonal cells / bone marrow). It is the same variant present in >90% of Waldenström macroglobulinemia, and is the leading molecular link between the inflammatory and lymphoproliferative arms (PMID:31228950; PMID:38927050). Variant: MYD88 (HGNC:7562) c.794T>C, p.Leu265Pro, somatic, gain-of-function. - Low-frequency somatic mosaic NLRP3 variants have been reported in occasional "Schnitzler-like" patients but are not a consistent finding.

Environmental / lifestyle risk factors. None established. Onset is age-related (typically >50 years); no confirmed occupational, infectious, dietary, or toxic trigger. Slight male predominance (see §9).

Protective factors. None identified (no protective alleles, no dietary/lifestyle protection described). This reflects how little is known about initiation rather than a true absence.

Gene–environment interaction. Not characterized. The plausible model is a somatic clonal lesion (MYD88 L265P → constitutive NF-κB priming) interacting with innate-immune inflammasome tone in an aging host, but this is mechanistic hypothesis, not established G×E data.

3. Phenotypes

Frequencies below are from the pooled 281-case review (PMID:25905009) unless noted. Onset is adult/late-onset (median 51 y); course is chronic, relapsing-remitting / episodic but lifelong without treatment.

Per-phenotype characteristics. - Rash: the hallmark — a neutrophilic urticarial dermatosis, NOT classic allergic wheals: lesions are usually non-pruritic (pruritus in only ~21%), each resolves within 24 h, leaves no scarring/purpura, and spares angioedema. Often the first manifestation, sometimes by years. - Fever: recurrent, intermittent, can be high but is characteristically well-tolerated; not strictly periodic (distinguishing it from hereditary periodic fevers). - Bone involvement: distal femur and proximal tibia osteosclerosis/hyperostosis is a relatively specific feature; bone scintigraphy shows increased uptake in ~85%. - Severity/progression: individually mild-to-moderate per flare but cumulatively debilitating; QoL is severely impaired pre-treatment and dramatically restored by IL-1 blockade.

Quality-of-life impact. Marked before treatment — chronic rash, recurrent fever, bone pain, and fatigue impair daily functioning; canakinumab/anakinra trials documented significant improvement in QoL scores alongside CRP/SAA normalization (PMID:27658762; PMID:23087179).

4. Genetic / Molecular Information

• Causal genes: None inherited. The disorder is acquired. The recurrent somatic driver is MYD88 (HGNC:7562; OMIM gene 602170; chr3p22.2), variant p.Leu265Pro (L265P) — gain-of-function, found in clonal cells of a subset of patients and the molecular bridge to Waldenström macroglobulinemia (PMID:31228950).
• NLRP3 (HGNC:16400): No germline or somatic NLRP3 variants by deep NGS in two cohorts (n=21, n=40) — explicitly distinguishing Schnitzler from CAPS (PMID:38927050). This negative finding is itself a key curatable fact.
• Variant classification / type: MYD88 L265P — missense, somatic, gain-of-function, dominant-acting at the cellular signaling level. Well established as pathogenic/oncogenic in B-cell lymphoma contexts (ClinVar/COSMIC); in Schnitzler it is a clonal somatic marker, not a germline disease allele.
• Allele frequency: Not a population polymorphism; somatic, absent from gnomAD as a germline variant.
• Functional consequence: L265P stabilizes a MYD88 multimer that constitutively engages IRAK4/IRAK1 → persistent NF-κB activation, priming transcription of NLRP3 and pro-IL-1β; it is also reported to resist caspase-1-mediated negative feedback of MyD88 signaling (PMID:38927050).
• Modifier genes / epigenetics / chromosomal abnormalities: Not characterized. No methylation signature, no recurrent karyotypic lesion described.

5. Environmental Information

• Environmental/occupational/toxin factors: None established.
• Lifestyle factors: None established.
• Infectious agents: None — Schnitzler is not infection-triggered. (NCBI Taxonomy / pathogen sections not applicable.) Fever and inflammation are sterile/autoinflammatory.

This section is genuinely sparse for this disease — the etiology is intrinsic (clonal + innate-immune), not exposure-driven.

6. Mechanism / Pathophysiology

Central axis: IL-1β-driven autoinflammation. The dominant, therapy-validated mechanism is overproduction/over-signaling of IL-1β, with the NLRP3 inflammasome as the assembly platform. The most compelling evidence is therapeutic: IL-1 blockade produces near-complete remission within hours (PMID:25905009; PMID:38927050).

Proposed causal chain (upstream → downstream):

1. Clonal/innate priming (upstream). A somatic lesion — prototypically MYD88 L265P — drives constitutive NF-κB activation in myeloid and/or clonal B-cells, providing a persistent "signal 1" that upregulates NLRP3 and pro-IL-1β transcription (PMID:31228950; PMID:38927050).
2. GO: GO:0007249 I-κB kinase/NF-κB signaling; GO:0002224 toll-like receptor signaling pathway (MyD88-dependent).
3. NLRP3 inflammasome activation ("signal 2"). Despite no NLRP3 mutation, the inflammasome is hyperactive: assembly of NLRP3–ASC–pro-caspase-1, caspase-1 autoactivation, cleavage of pro-IL-1β → mature IL-1β; pyroptotic release marked by elevated extracellular ASC specks (PMID:38927050).
4. GO: GO:0002218 activation of innate immune response; GO:0072559 NLRP3 inflammasome complex (CC); GO:0050700 CARD domain binding; GO:0097202 activation of cysteine-type endopeptidase activity; GO:0070269 pyroptosis.
5. Cytokine cascade (downstream). Elevated IL-1β, IL-6, IL-18; IL-6 drives the acute-phase response (CRP, serum amyloid A), fever, and anemia of inflammation.
6. GO: GO:0050715 positive regulation of cytokine secretion; GO:0006954 inflammatory response; GO:0061702 canonical inflammasome complex.
7. Effector cells. Dermal mast cells identified as a primary IL-1β source in lesional skin (PMID:38927050); neutrophils recruited into the dermis produce the characteristic neutrophilic urticarial dermatosis (interstitial/perivascular neutrophilic infiltrate, leukocytoclasis, no vasculitis, no dermal edema).
8. CL: CL:0000097 mast cell; CL:0000775 neutrophil; CL:0000235 macrophage; CL:0000786 plasma cell / CL:0000787 memory B cell (clonal compartment).
9. Clinical manifestations. Rash (neutrophilic urticaria), fever, bone remodeling (osteosclerosis), arthralgia, fatigue.

Bone phenotype mechanism. IL-1/IL-6-driven abnormal bone remodeling produces osteosclerosis/hyperostosis (paradoxically osteoblastic), most marked at distal femur/proximal tibia — a relatively specific imaging clue.

Immune system involvement. Prototypic autoinflammation (innate, antigen-independent) layered on a clonal B-cell/plasma-cell process. Not classic autoimmunity (no pathogenic autoantibody to self), though the monoclonal IgM is sometimes proposed to contribute (e.g., complement engagement) — unproven.

Molecular profiling. Serum cytokine studies show elevated IL-6/IL-18 and modestly elevated IL-1β; lesional skin transcriptomic/IHC work localizes IL-1β to mast cells. No large -omics (proteomic/metabolomic/single-cell) signature is yet established — a genuine knowledge gap.

Protein dysfunction (UniProt anchors): MYD88 (UniProt Q99836); NLRP3/cryopyrin (Q96P20); IL-1β (P01584); caspase-1 (P29466); ASC/PYCARD (Q9ULZ3).

7. Anatomical Structures Affected

• Skin (primary): UBERON:0002097 skin of body / UBERON:0002067 dermis — site of neutrophilic urticarial dermatosis. Lesions favor trunk and limbs, spare the face; bilateral/generalized.
• Bone (primary, characteristic): UBERON:0002481 bone tissue; specifically distal femur (UBERON:0009980) and proximal tibia / tibia (UBERON:0000979) osteosclerosis; iliac bone involvement also described.
• Joints (secondary): UBERON:0000982 skeletal joint — non-erosive arthralgia/arthritis, large joints.
• Lymphoid / hematopoietic: UBERON:0000029 lymph node (reactive lymphadenopathy); UBERON:0002106 spleen, UBERON:0002107 liver (occasional organomegaly); bone marrow (UBERON:0002371) — clonal plasma/B-cell compartment.
• Blood: UBERON:0000178 blood — monoclonal protein, leukocytosis, anemia, acute-phase reactants.
• Body systems: integumentary, musculoskeletal, hematologic/lymphatic, and (systemically) immune.
• Subcellular (GO CC): GO:0072559 NLRP3 inflammasome complex; GO:0005829 cytosol (inflammasome assembly); GO:0005886 plasma membrane (IL-1R signaling).
• Lateralization: rash and bone changes are typically bilateral/symmetric/generalized.

8. Temporal Development

• Onset: Adult/late-onset — median age ~51 years (PMID:25905009); onset before 35 is rare; essentially never congenital/pediatric.
• Onset pattern: Insidious/chronic, frequently beginning with isolated chronic urticaria; the monoclonal protein and full systemic picture may emerge over months to years.
• Course: Chronic, relapsing-remitting / episodic flares of rash and fever on a background of persistent inflammation; lifelong without treatment. Spontaneous complete remission is exceptionally rare ("only one case" reported, PMID:38927050).
• Progression / critical windows:
• AA amyloidosis can develop after years of uncontrolled inflammation — a window where sustained IL-1 blockade is preventive.
• Lymphoproliferative transformation (Waldenström macroglobulinemia / lymphoplasmacytic lymphoma) emerges at a median ~8 years after onset (range often cited 10–20 y), mandating long-term hematologic surveillance.
• Treatment-induced remission: IL-1 blockade induces rapid (hours-to-days), reproducible clinical remission, but is suppressive, not curative — symptoms recur within 24–48 h of stopping anakinra.

9. Inheritance and Population

• Epidemiology: Rare. Prevalence unknown; ~300 cases published worldwide (≈150 in earlier counts, growing), predominantly European/Caucasian, reported in >25 countries. Orphanet classes it as rare (ORPHA:37748).
• Inheritance: Not heritable — acquired/sporadic. No AD/AR/X-linked/mitochondrial pattern; no penetrance/expressivity/anticipation/founder-effect/carrier-frequency concepts apply. (These template sub-items are not applicable.)
• Demographics:
• Sex ratio ~1.5:1 male:female (slight male predominance) (PMID:25905009).
• Immunoglobulin profile: monoclonal IgMκ in ~85% (IgMλ ~8%), IgG ~6%; kappa light chain in ~89% overall.
• Geographic: apparent European concentration likely reflects ascertainment/awareness rather than true biology.

10. Diagnostics

Diagnostic criteria — Strasbourg criteria (2012/2013 expert consensus; validated by Gusdorf et al. 2017, Allergy, DOI:10.1111/all.13035).

Two obligate criteria (both required): 1. Chronic urticarial rash, AND 2. Monoclonal IgM or IgG

Minor criteria: - Recurrent fever (>38 °C, no other cause) - Objective signs of abnormal bone remodeling (with or without bone pain) — e.g., osteosclerosis/hyperostosis on imaging/scintigraphy - Neutrophilic dermal infiltrate on skin biopsy (neutrophilic urticarial dermatosis, no vasculitis/edema) - Leukocytosis (neutrophils >10,000/mm³) and/or elevated CRP (>30 mg/L)

Definite diagnosis: 2 obligate + ≥2 minor (IgM) or ≥3 minor (IgG). Probable diagnosis: 2 obligate + ≥1 minor (IgM) or ≥2 minor (IgG).

Laboratory workup (LOINC-codable analytes): - Serum protein electrophoresis + immunofixation → monoclonal IgM (κ) — the obligate gammopathy. - CRP (LOINC 1988-5), ESR, serum amyloid A — markedly elevated; track disease/treatment. - CBC — neutrophilic leukocytosis, anemia of chronic disease. - MYD88 L265P assay on peripheral blood/bone marrow in selected patients (links to Waldenström risk). - Bone marrow biopsy to exclude/monitor lymphoplasmacytic disorder.

Imaging: plain radiographs (hyperostosis ~39%), bone scintigraphy (increased uptake ~85% — sensitive for the osteosclerotic lesions), MRI/PET for marrow/bone.

Histopathology (skin biopsy): neutrophilic urticarial dermatosis — perivascular and interstitial neutrophils with leukocytoclasis, without true vasculitis and without significant dermal edema.

Differential diagnosis (with distinguishing features): - CAPS / Muckle-Wells / NOMID — germline NLRP3, childhood onset, sensorineural deafness; Schnitzler is adult, no NLRP3 mutation, has gammopathy. - Adult-onset Still disease — ferritin-high, salmon rash, no monoclonal protein. - Chronic spontaneous urticaria — pruritic, no fever/gammopathy/bone disease. - Urticarial vasculitis — true leukocytoclastic vasculitis, lesions >24 h with purpura. - Waldenström macroglobulinemia / IgM-MGUS — the gammopathy overlaps; Schnitzler adds the autoinflammatory phenotype. - Hyper-IgD / TRAPS / other periodic fevers — hereditary, earlier onset.

Screening: No population/newborn screening (acquired, rare). Surveillance is longitudinal — periodic monoclonal-protein quantitation and clinical/hematologic monitoring for lymphoproliferative transformation and amyloidosis.

11. Outcome / Prognosis

• Survival: Generally good/near-normal life expectancy in the IL-1-blockade era; mortality is driven not by the inflammation itself but by its complications.
• Major complications:
• Lymphoproliferative malignancy in ~15–20% (Waldenström macroglobulinemia most common; also lymphoplasmacytic lymphoma, rarely IgM myeloma), typically after 10–20 years; pooled review found 12% (35/281) at median 8-year follow-up — true lifetime risk likely higher (PMID:25905009).
• AA (secondary) amyloidosis in ~2% (6/281) from chronic SAA elevation — historically a cause of renal failure/death; preventable by controlling inflammation.
• Anemia of chronic inflammation, fatigue, debilitating QoL pre-treatment.
• Recovery potential: Inflammation is highly controllable (IL-1 blockade), but the disease is chronic/lifelong and treatment is suppressive, not curative; the monoclonal gammopathy and malignancy risk are not altered by IL-1 inhibitors.
• Prognostic factors: duration of uncontrolled inflammation (amyloidosis risk), rising/transforming monoclonal component, evolving cytopenias or organomegaly (lymphoma signal). SAA/CRP serve as activity and amyloid-risk biomarkers.

12. Treatment

First-line: IL-1 blockade — the defining, near-pathognomonic therapy (MAXO:0000058 anti-inflammatory agent therapy / MAXO:0000986-type targeted biologic; treatment action = NCIT:C15986 Pharmacotherapy with biologic therapeutic_agent).

1. Anakinra (recombinant IL-1 receptor antagonist; CHEBI:472604 anakinra / NCIT:C1598 Anakinra).
2. Most established therapy; complete remission in >90% of cases (81/86 patients high efficacy, PMID:25905009). Symptoms resolve within hours; relapse 24–48 h after stopping (short half-life ~3–9.5 h → daily SC dosing).
3. Therapeutic modality: protein/antagonist biologic; MAXO/NCIT pharmacotherapy.
4. Canakinumab (anti-IL-1β monoclonal antibody; NCIT:C75984 Canakinumab; modality MONOCLONAL_ANTIBODY).
5. Randomized, placebo-controlled trial evidence: complete clinical response at day 7 in 5/7 canakinumab vs 0/13 placebo (P=.001), with significant CRP/SAA and QoL improvement (PMID:27658762; PMC4597402). 9-month open trial: remission in all 8 patients by day 14, sustained (PMID:23087179). Long half-life (~3–4 weeks) → monthly (or longer) dosing. First choice for anakinra-refractory patients.
6. Rilonacept (IL-1 decoy receptor, binds IL-1α/β; NCIT:C66952 Rilonacept) — open-label efficacy (8-patient cohort); weekly SC.

Second-line / alternatives: - Tocilizumab (anti-IL-6R) — initial response then waning efficacy in a 9-patient series. - Ibrutinib (BTK inhibitor) — case-level efficacy with a rational dual benefit (inflammasome + MYD88-driven clonal disease). - Colchicine (~1 mg/day) — mild disease/adjunct. - Anti-IgM / B-cell–directed (rituximab) when an overt lymphoplasmacytic disorder coexists. - NSAIDs, corticosteroids, conventional immunosuppressants — historically used, generally only partially effective and steroid-sparing is a goal.

Pharmacogenomics: MYD88 L265P status is the actionable molecular marker — flags Waldenström risk and provides biologic rationale for BTK inhibition; no validated PK/PGx-by-genotype dosing.

Treatment strategy / outcomes: Algorithm = confirm Strasbourg criteria → start anakinra (also a diagnostic test, given the dramatic response) → switch to canakinumab/rilonacept for convenience or anakinra failure → escalate to B-cell-directed/BTK therapy if clonal disease progresses. IL-1 blockade reverses inflammation, normalizes acute-phase reactants, restores QoL, and is expected to prevent AA amyloidosis — but does not prevent lymphoproliferative transformation. Adverse events (canakinumab trials): respiratory and GI infections, neutropenia, injection-site reactions.

Suggested MAXO terms: MAXO:0000058 (anti-inflammatory agent therapy); MAXO:0001013-type biologic/immunomodulatory therapy; broad action NCIT:C15986 Pharmacotherapy with therapeutic_agent biologics (anakinra/canakinumab/rilonacept) — per dismech therapeutic-agent pattern, prefer NCIT agent terms for biologics lacking clean CHEBI entries.

13. Prevention

• Primary prevention: None — etiology unknown, acquired, no modifiable risk factor or vaccine.
• Secondary prevention: Early recognition (apply Strasbourg criteria to "chronic urticaria + monoclonal IgM") shortens diagnostic delay (historically years).
• Tertiary prevention (the real lever):
• Sustained IL-1 blockade to prevent AA amyloidosis (by normalizing SAA).
• Long-term hematologic surveillance (serial monoclonal-protein quantitation, exam, blood counts) for early detection of Waldenström/lymphoplasmacytic transformation.
• Counseling: Not genetic counseling (not heritable) — rather patient education on chronicity, the need for ongoing therapy, and malignancy monitoring.
• Public health / immunization / environmental measures: Not applicable.

14. Other Species / Natural Disease

Not applicable / none reported. Schnitzler syndrome is a human-only acquired syndrome; there is no naturally occurring animal counterpart (no OMIA entry), no breed predisposition, and no zoonotic/cross-species dimension. The relevant gene MYD88 is highly conserved (orthologs across vertebrates), but no animal exhibits the Schnitzler clinical syndrome. NCBI Taxon for the affected species: NCBITaxon:9606 (Homo sapiens) only.

15. Model Organisms

No dedicated animal model exists. Because the disorder is acquired, somatic, and tied to an aging human clonal/innate-immune context, it has not been recapitulated in mice, zebrafish, or other model organisms. Mechanistic insight comes from: - In vitro / ex vivo human studies (patient PBMCs, monocytes, lesional skin) demonstrating NLRP3-inflammasome hyperactivity, IL-1β/IL-18 elevation, ASC-speck release, and mast-cell IL-1β localization (PMID:38927050) — evidence_source IN_VITRO / HUMAN_CLINICAL. - Cellular MYD88 L265P models (from Waldenström/lymphoma biology) informing the NF-κB-priming mechanism — relevant but not Schnitzler-specific.

This is a genuine knowledge gap: a faithful model would need to reproduce the somatic-clonal + autoinflammatory overlap, which no current system does. (Appropriate dismech treatment: a KNOWLEDGE_GAP discussion noting absence of an animal model, not a fabricated MODEL_ORGANISM evidence item.)

Curation Notes & Suggested Evidence Anchors

High-value PMIDs (fetch + snippet-validate before use): - PMID:25905009 — de Koning HD. Schnitzler's syndrome: lessons from 281 cases. (Pooled frequencies, demographics, malignancy 12%, amyloidosis 2%, anakinra >90% response.) — primary epidemiology source. - PMID:38927050 — Braud A, Lipsker D. Schnitzler Syndrome: Insights into Its Pathogenesis, Clinical Manifestations, and Current Management. Biomolecules 2024;14(6):646. — best recent mechanism + management review. - PMID:27658762 — Krause K, et al. Efficacy and safety of canakinumab in Schnitzler syndrome: a multicenter randomized placebo-controlled study. — RCT (HUMAN_CLINICAL, the strongest treatment evidence). - PMID:23087179 — Vanderschueren S, Knockaert D. Sustained efficacy of canakinumab... 9-month trial. — open-label trial. - PMID:31228950 — Schnitzler's syndrome — a novel hypothesis of a shared pathophysiologic mechanism with Waldenström's disease (MYD88 L265P link). - DOI:10.1111/all.13035 (Gusdorf 2017, Allergy) — Strasbourg criteria validation. - ORPHA:37748 — Orphanet record (structured-source citable for definition/prevalence/synonyms).

Suggested module conformance for the dismech entry: - The disease is a strong candidate to reference an IL-1/inflammasome autoinflammation pattern. There is no existing dedicated NLRP3/IL-1 module in the listed module set, but the mechanism centers on NLRP3 inflammasome → IL-1β; consider whether a new il1_inflammasome_autoinflammation module is warranted (flag as design decision) rather than forcing conformance to an unrelated module. - AA amyloidosis as a downstream complication and lymphoproliferative transformation (Waldenström) are good candidates for comorbidity/trajectory entries rather than core pathophysiology nodes.

Evidence-source tagging reminders: Treatment RCTs and case series → HUMAN_CLINICAL; inflammasome/cytokine cell work → IN_VITRO; the MYD88 L265P NF-κB mechanism drawn from lymphoma cell models → IN_VITRO (and note it is extrapolated, not Schnitzler-derived). No MODEL_ORGANISM evidence is available — do not invent it.

Sources

• Schnitzler Syndrome: Insights into Its Pathogenesis, Clinical Manifestations, and Current Management (Biomolecules 2024, PMID:38927050)
• Schnitzler's syndrome: lessons from 281 cases (PMID:25905009)
• Background and Clinical Features of Schnitzler Syndrome (IJMS / MDPI 2025)
• Schnitzler's syndrome — shared pathophysiologic mechanism with Waldenström's disease (PMID:31228950)
• The role of interleukin-1 beta in the pathophysiology of Schnitzler's syndrome (PMC4511239)
• Strasbourg criteria validation in real-life patients (Gusdorf 2017, Allergy)
• Two cases successfully treated with anakinra (Case Reports in Rheumatology 2018)
• Canakinumab multicenter randomized placebo-controlled study (PMID:27658762 / PMC4597402)
• Sustained efficacy of canakinumab, 9-month trial (PMID:23087179)
• Orphanet: Schnitzler syndrome (ORPHA:37748)
• The Schnitzler syndrome (Orphanet J Rare Dis review, PMC3018454)

Verify before committing: MONDO:0008756 label/ID via OAK; exact HPO term IDs/labels (esp. the monoclonal IgM phenotype term); and every snippet as an exact substring of its cached abstract per the dismech anti-hallucination SOP — especially the MYD88/NLRP3 mechanistic claims, which are the highest-risk for paraphrase drift.